Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a commercial medical
technology company that designs, produces and markets safe and effective
tissue care products based upon the Microcyn® Technology platform, today
unveiled Microcyn Solution with preservatives, at the New York Podiatric
Clinical Conference & Exhibition being held in downtown Manhattan,
January 29-31.
The Microcyn® Solution for professional use is intended for the
irrigation and management via debridement of post-surgical wounds.
Available in 500 mL and 990 mL units with attached pharmasling® hangers,
Microcyn Solution has no known drug/treatment interactions or
contraindications; is non-foaming and safe to use around nose, mouth and
eyes; does not contain antibiotics and will not facilitate bacterial
resistance. With a laboratory-proven inactivation of bacteria, fungus
and spores in-solution, Microcyn delivers a six-log reduction of MRSA,
VRE, Pseudomonas, Acinetobacter and many other pathogens
in just 30 seconds as labeled and cleared by the FDA. The patented
Microcyn Solution can be easily and harmlessly disposed of without the
added cost of special handling. The Microcyn Technology has treated over
two million patients worldwide and has been used in 30 clinical studies,
all without a report of a single serious adverse effect.
For more information, pricing or ordering visit http://store.oculusis.com/
or phone 1-800-931-3205.